The extraordinary general meeting resolved to approve the board of directors' resolution on issuance of new shares with deviation from the shareholders' preferential rights.

As communicated in the Company's press releases from 26 September 2023, the Company's board of directors had resolved on a directed issue of in total 26,315,790 shares at a subscription price of SEK 5.7 per share, consequently raising gross proceeds of approximately SEK 150 million. 17,835,782 shares were issued based on the issue authorization granted by the annual general meeting on 31 May 2023, and the remaining 8,480,008 shares were issued subject to the subsequent approval of an extraordinary general meeting.

The new share issue entails an increase of the Company's share capital by a maximum of SEK 530,000.50 through the issuance of a maximum of 8,480,008 shares, each with a quota value of SEK 0.0625.

The rationale for carrying out the share issue is to secure financing of the Company's operations and previously communicated strategy shift. The board of directors has made an overall assessment and carefully considered the possibility to raise capital through a rights issue with preferential right for the Company's existing shareholders. The board of directors considers that the reasons for deviating from the shareholders' preferential right are (i) that a rights issue would take a significantly longer time to complete and entail a higher risk for an adverse effect on the share price, particularly in light of the current market volatility and the challenging market conditions, (ii) to diversify and strengthen the Company's shareholder base with institutional investors, (iii) to carry out a directed share issue can be made at lower costs and with less complexity than a rights issue and in light of the current market conditions, the board of directors has assessed that a rights issue would also require external underwriting from a guarantor syndicate that would entail additional significant costs. Considering the above, the board of directors has made the assessment that a directed share issue with deviation from the shareholders' preferential right is the most favourable alternative for the Company to finance the announced new strategy, creates value for the Company and is in the best interest of the Company's shareholders. The board of directors thus considers that the reasons outweigh the main rule that new share issues are to be carried out with preferential rights for the shareholders.

For more information on the new share issue, please refer to the press releases published on the Company's website on 26 September 2023.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Mob: +46 73 382 43 90
morten.henneveld@ossdsign.com

Certified Adviser:

Erik Penser Bank AB is the Company's Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

The information was submitted for publication, through the agency of the contact persons set out above, on 16 October 2023, 11:00 CET.

About OssDsign

OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body's own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign's share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.